| Drug Type Chemical drugs | 
| Synonyms LYZA 3, LYZA3 | 
| Target | 
| Action inhibitors | 
| Mechanism α-synuclein inhibitors(Synuclein alpha inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Parkinson Disease | Preclinical | Japan  | 25 Jun 2024 | 





